Pathology of breast and ovarian cancers among BRCA1 and BRCA2 mutation carriers: Results from the consortium of investigators of modifiers of BRCA1/2 (CIMBA)

Cancer Epidemiology Biomarkers and Prevention

Volumn 21, Issue 1, 2012, Pages 134-147

  Mavaddat, Nasim ^a   Barrowdale, Daniel ^a   Andrulis, Irene L ^b,d   Domchek, Susan M ^g   Eccles, Diana ⁱ   Nevanlinna, Heli ^j   Ramus, Susan J ^k   Spurdle, Amanda ^m   Robson, Mark ^c   Sherman, Mark ⁿ   Mulligan, Anna Marie ^d,e   Couch, Fergus J ^o   Engel, Christoph ^p   McGuffog, Lesley ^a   Healey, Sue ^m   Sinilnikova, Olga M ^q,r   Southey, Melissa C ^s   Terry, Mary Beth ^c   Goldgar, David ^u   O'Malley, Frances ^b,d   John, Esther M ^v   Janavicius, Ramunas ^w   Tihomirova, Laima ^x   Hansen, Thomas V O ^y   Nielsen, Finn C ^z   Osorio, Ana ^aa   Stavropoulou, Alexandra ^ac   Benítez, Javier ^ab   Manoukian, Siranoush ^ad   Peissel, Bernard ^ad   Barile, Monica ^ae   Volorio, Sara ^af   Pasini, Barbara ^ag   Dolcetti, Riccardo ^ah   Putignano, Anna Laura ^ai   Ottini, Laura ^aj   Radice, Paolo ^ad,af   Hamann, Ute ^ak   Rashid, Muhammad U ^ak,am   Hogervorst, Frans B ^an   Kriege, Mieke ^ao   Van Der Luijt, Rob B ^ap   Peock, Susan ^a   Frost, Debra ^a   Evans, D Gareth ^aq   Brewer, Carole ^ar   Walker, Lisa ^as   Rogers, Mark T ^at   Side, Lucy E ^au   Houghton, Catherine ^av   Weaver, JoEllen ^h   Godwin, Andrew K ^aw   Schmutzler, Rita K ^ax   Wappenschmidt, Barbara ^ax   Meindl, Alfons ^ay   Kast, Karin ^az   Arnold, Norbert ^ba   Niederacher, Dieter ^bb   Sutter, Christian ^al   Deissler, Helmut ^bc   Gadzicki, Doroteha ^bd   Preisler Adams, Sabine ^be   Varon Mateeva, Raymonda ^bf   Schönbuchner, Ines ^bg   Gevensleben, Heidrun ^bh   Stoppa Lyonnet, Dominique ^bi,bj,bk   Belotti, Muriel ^bi   Barjhoux, Laure ^r   Isaacs, Claudine ^bl   Peshkin, Beth N ^bl   Caldes, Trinidad ^ab   De Al Hoya, Miguel ^ac   Cañadas, Carmen ^ac   Heikkinen, Tuomas ^j   Heikkilä, Päivi ^j   Aittomäki, Kristiina ^j   Blanco, Ignacio ^bm   Lazaro, Conxi ^bm   Brunet, Joan ^bn   Agnarsson, Bjarni A ^bo   Arason, Adalgeir ^bo   Barkardottir, Rosa B ^bo   Dumont, Martine ^bp   Simard, Jacques ^bp   Montagna, Marco ^bq   Agata, Simona ^bq   D'Andrea, Emma ^br   Yan, Max ^bs   Fox, Stephen ^t   Rebbeck, Timothy R ^f   Rubinstein, Wendy ^bt   Tung, Nadine ^bu   Garber, Judy E ^bv   Wang, Xianshu ^o   Fredericksen, Zachary ^o   Pankratz, Vernon S ^o   Lindor, Noralane M ^o   Szabo, Csilla ^bw   Offit, Kenneth ^c   Sakr, Rita ^c   Gaudet, Mia M ^bx   Singer, Christian F ^by   Tea, Muy Kheng ^by   Rappaport, Christine ^by   Mai, Phuong L ⁿ   Greene, Mark H ⁿ   Sokolenko, Anna ^bz   Imyanitov, Evgeny ^bz   Toland, Amanda Ewart ^ca   Senter, Leigha ^cb   Sweet, Kevin ^cb   Thomassen, Mads ^cc   Gerdes, Anne Marie ^z   Kruse, Torben ^cc   Caligo, Maria ^cd   Aretini, Paolo ^cd   Rantala, Johanna ^ce   Von Wachenfeld, Anna ^ce   Henriksson, Karin ^cf   Steele, Linda ^cg   Neuhausen, Susan L ^cg   Nussbaum, Robert ^ch   Beattie, Mary ^ci   Odunsi, Kunle ^cj   Sucheston, Lara ^cj   Gayther, Simon A ^k   Nathanson, Kate ^g   Gross, Jenny ^l   Walsh, Christine ^l   Karlan, Beth ^l   Chenevix Trench, Georgia ^m   Easton, Douglas F ^a   Antoniou, Antonis C ^a   more..

^a UNIVERSITY OF CAMBRIDGE   (United Kingdom)

^b MOUNT SINAI HOSPITAL   (United States)

^c Och Spine at New York Presbyterian Hospitals   (United States)

^d UNIVERSITY OF TORONTO   (Canada)

^e ST MICHAEL'S HOSPITAL   (Canada)

^f UNIVERSITY OF PENNSYLVANIA   (United States)

^g UNIVERSITY OF PENNSYLVANIA   (United States)

^h FOX CHASE CANCER CENTER   (United States)

ⁱ UNIVERSITY OF SOUTHAMPTON   (United Kingdom)

^j HELSINKI UNIVERSITY CENTRAL HOSPITAL   (Finland)

^k UNIVERSITY OF SOUTHERN CALIFORNIA   (United States)

^l CEDARS SINAI MEDICAL CENTER   (United States)

^m QIMR BERGHOFER MEDICAL RESEARCH INSTITUTE   (Australia)

ⁿ NATIONAL CANCER INSTITUTE   (United States)

^o MAYO CLINIC   (United States)

^p UNIVERSITY OF LEIPZIG   (Germany)

^q HOSPICES CIVILS DE LYON   (France)

^r CENTRE DE RECHERCHE EN CANCÉROLOGIE DE LYON   (France)

^s UNIVERSITY OF MELBOURNE   (Australia)

^t PETER MACCALLUM CANCER CENTRE   (Australia)

^u UNIVERSITY OF UTAH SCHOOL OF MEDICINE   (United States)

^v CANCER PREVENTION INSTITUTE OF CALIFORNIA   (United States)

^w VILNIUS UNIVERSITY   (Lithuania)

^x LATVIAN BIOMEDICAL RESEARCH AND STUDY CENTRE   (Latvia)

^y Rigshospitalet   (Denmark)

^z UNIVERSITY OF COPENHAGEN   (Denmark)

^aa CENTRO DE INVESTIGACIÓN BIOMÉDICA EN RED DE ENFERMEDADES RARAS CIBERER   (Spain)

^ab HOSPITAL CLÍNICO SAN CARLOS   (Spain)

^ac INSTITUTE OF NANOSCIENCE AND NANOTECHNOLOGY   (Greece)

^ad NATIONAL CANCER INSTITUTE   (Italy)

^ae EUROPEAN INSTITUTE OF ONCOLOGY   (Italy)

^af FIRC INSTITUTE OF MOLECULAR ONCOLOGY   (Italy)

^ag UNIVERSITY OF TURIN   (Italy)

^ah CENTRO DI RIFERIMENTO ONCOLOGICO   (Italy)

^ai UNIVERSITY OF FLORENCE   (Italy)

^aj SAPIENZA UNIVERSITY OF ROME   (Italy)

^ak GERMAN CANCER RESEARCH CENTER DKFZ   (Germany)

^al UNIVERSITY HOSPITAL HEIDELBERG   (Germany)

^am SHAUKAT KHANUM MEMORIAL CANCER HOSPITAL AND RESEARCH CENTRE   (Pakistan)

^an Family Cancer Clinic   (Netherlands)

^ao ERASMUS MEDICAL CENTER   (Netherlands)

^ap UNIVERSITY MEDICAL CENTER UTRECHT   (Netherlands)

^aq UNIVERSITY OF MANCHESTER   (United Kingdom)

^ar ROYAL DEVON AND EXETER HOSPITAL   (United Kingdom)

^as CHURCHILL HOSPITAL   (United Kingdom)

^at UNIVERSITY HOSPITAL OF WALES   (United Kingdom)

^au GREAT ORMOND STREET HOSPITAL   (United Kingdom)

^av LIVERPOOL WOMEN'S NHS FOUNDATION TRUST   (United Kingdom)

^aw UNIVERSITY OF KANSAS SCHOOL OF MEDICINE   (United States)

^ax UNIVERSITY HOSPITAL OF COLOGNE   (Germany)

^ay TECHNICAL UNIVERSITY OF MUNICH   (Germany)

^az UNIVERSITY HOSPITAL CARL GUSTAV CARUS   (Germany)

^ba UNIVERSITY HOSPITAL SCHLESWIG HOLSTEIN   (Germany)

^bb UNIVERSITY HOSPITAL DÜSSELDORF   (Germany)

^bc UNIVERSITY HOSPITAL ULM   (Germany)

^bd HANNOVER MEDICAL SCHOOL   (Germany)

^be UNIVERSITY OF MÜNSTER   (Germany)

^bf CHARITÉ UNIVERSITÄTSMEDIZIN BERLIN   (Germany)

^bg UNIVERSITY OF WÜRZBURG   (Germany)

^bh INSTITUTE OF CANCER RESEARCH   (United Kingdom)

^bi Service de Génétique Oncologique   (France)

^bj INSTITUT CURIE   (France)

^bk UNIVERSITÉ PARIS DESCARTES   (France)

^bl GEORGETOWN UNIVERSITY   (United States)

^bm HOSPITAL DURAN I REYNALS   (Spain)

^bn GIRONA BIOMEDICAL RESEARCH INSTITUTE IDIBGI   (Spain)

^bo LANDSPITALI UNIVERSITY HOSPITAL   (Iceland)

^bp LAVAL UNIVERSITY   (Canada)

^bq VENETO INSTITUTE OF ONCOLOGY IOV IRCCS   (Italy)

^br UNIVERSITY OF PADOVA   (Italy)

^bs PRINCE OF WALES HOSPITAL   (Australia)

^bt NORTHSHORE UNIVERSITY HEALTHSYSTEM   (United States)

^bu Medical Oncology   (Israel)

^bv DANA FARBER CANCER INSTITUTE   (United States)

^bw UNIVERSITY OF DELAWARE   (United States)

^bx AMERICAN CANCER SOCIETY   (United States)

^by MEDICAL UNIVERSITY OF VIENNA   (Austria)

^bz N N PETROV RESEARCH INSTITUTE OF ONCOLOGY   (Russian Federation)

^ca THE OHIO STATE UNIVERSITY WEXNER MEDICAL CENTER   (United States)

^cb OHIO STATE UNIVERSITY   (United States)

^cc ODENSE UNIVERSITY HOSPITAL   (Denmark)

^cd UNIVERSITY HOSPITAL OF PISA   (Italy)

^ce KAROLINSKA UNIVERSITY HOSPITAL   (Sweden)

^cf LUND UNIVERSITY HOSPITAL   (Sweden)

^cg CITY OF HOPE NATIONAL MEDICAL CENTER   (United States)

^ch UNIVERSITY OF CALIFORNIA   (United States)

^ci UNIVERSITY OF CALIFORNIA   (United States)

^cj ROSWELL PARK CANCER INSTITUTE   (United States)

more..

Author keywords

[No Author keywords available]

Indexed keywords

BRCA1 PROTEIN; BRCA2 PROTEIN; CARRIER PROTEIN; ESTROGEN RECEPTOR; PROGESTERONE RECEPTOR;

ADULT; ARTICLE; BREAST CANCER; BREAST TUMOR; CANCER GRADING; CANCER INVASION; CANCER MORPHOLOGY; CANCER PREVENTION; CANCER SCREENING; DISEASE ASSOCIATION; FEMALE; GENE MUTATION; HUMAN; NUCLEOTIDE SEQUENCE; OVARY CANCER; PREDICTION; PRIORITY JOURNAL; PROTEIN EXPRESSION; TUMOR CLASSIFICATION;

EID: 84862907494     PISSN: 10559965     EISSN: None     Source Type: Journal    
DOI: 10.1158/1055-9965.EPI-11-0775     Document Type: Article

References (47)

1. Armes JE, Egan AJ, Southey MC, Dite GS, McCredie MR, Giles GG, et al. The histologic phenotypes of breast carcinoma occurring before age 40 years in women with and without BRCA1 or BRCA2 germline mutations: a population-based study. Cancer 1998;83:2335-45. (Pubitemid 28533503)
2. Lakhani SR, Jacquemier J, Sloane JP, Gusterson BA, Anderson TJ, Van De Vijver MJ, et al. Multifactorial analysis of differences between sporadic breast cancers and cancers involving BRCA1 and BRCA2 mutations. J Natl Cancer Inst 1998;90:1138-45. (Pubitemid 28380718)
3. Southey MC, Ramus SJ, Dowty JG, Smith LD, Tesoriero AA, Wong EE, et al. Morphological predictors of BRCA1 germline mutations in young women with breast cancer. Br J Cancer 2011;104:903-9.
4. Eisinger F, Jacquemier J, Charpin C, Stoppa-Lyonnet D, Bressac-de PB, Peyrat JP, et al. Mutations at BRCA1: the medullary breast carcinoma revisited. Cancer Res 1998;58:1588-92. (Pubitemid 28215075)
5. Iau PT, Marafie M, Ali A, Sng JH, Macmillan RD, Pinder S, et al. Are medullary breast cancers an indication for BRCA1 mutation screening? A mutation analysis of 42 cases of medullary breast cancer. Breast Cancer Res Treat 2004;85:81-8. (Pubitemid 38437984)
6. Lakhani SR, Van De Vijver MJ, Jacquemier J, Anderson TJ, Osin PP, McGuffog L, et al. The pathology of familial breast cancer: predictive value of immunohistochemical markers estrogen receptor, progesterone receptor, HER-2, and p53 in patients with mutations in BRCA1 and BRCA2. J Clin Oncol 2002;20:2310-8. (Pubitemid 34441658)
7. Phillips KA. Immunophenotypic and pathologic differences between BRCA1 and BRCA2 hereditary breast cancers. J Clin Oncol 2000;18:107S-12S.
8. Tung N, Wang Y, Collins LC, Kaplan J, Li H, Gelman R, et al. Estrogen receptor positive breast cancers in BRCA1 mutation carriers: clinical risk factors and pathologic features. Breast Cancer Res 2010;12:R12.
9. Armes JE, Trute L, White D, Southey MC, Hammet F, Tesoriero A, et al. Distinct molecular pathogeneses of early-onset breast cancers in BRCA1 and BRCA2 mutation carriers: a population-based study. Cancer Res 1999;59:2011-7. (Pubitemid 29186179)
10. Atchley DP, Albarracin CT, Lopez A, Valero V, Amos CI, Gonzalez-Angulo AM, et al. Clinical and pathologic characteristics of patients with BRCA-positive and BRCA-negative breast cancer. J Clin Oncol 2008;26:4282-8.
11. Cortesi L, Turchetti D, Bertoni C, Bellei R, Mangone L, Vinceti M, et al. Comparison between genotype and phenotype identifies a high-risk population carrying BRCA1 mutations. Genes Chromosomes Cancer 2000;27:130-5. (Pubitemid 30030310)
12. Foulkes WD, Metcalfe K, Sun P, Hanna WM, Lynch HT, Ghadirian P, et al. Estrogen receptor status in BRCA1- and BRCA2-related breast cancer: the influence of age, grade, and histological type. Clin Cancer Res 2004;10:2029-34. (Pubitemid 38375563)
13. Johannsson OT, Idvall I, Anderson C, Borg A, Barkardottir RB, Egilsson V, et al. Tumour biological features of BRCA1-induced breast and ovarian cancer. Eur J Cancer 1997;33:362-71.
14. Karp SE, Tonin PN, Begin LR, Martinez JJ, Zhang JC, Pollak MN, et al. Influence of BRCA1 mutations on nuclear grade and estrogen receptor status of breast carcinoma in Ashkenazi Jewish women. Cancer 1997;80:435-41. (Pubitemid 27323413)
15. Loman N, Johannsson O, Bendahl PO, Borg A, Ferno M, Olsson H. Steroid receptors in hereditary breast carcinomas associated with BRCA1 or BRCA2 mutations or unknown susceptibility genes. Cancer 1998;83:310-9. (Pubitemid 28317811)
16. Palacios J, Honrado E, Osorio A, Cazorla A, Sarrio D, Barroso A, et al. Phenotypic characterization of BRCA1 and BRCA2 tumors based in a tissue microarray study with 37 immunohistochemical markers. Breast Cancer Res Treat 2005;90:5-14. (Pubitemid 40486996)
17. Lakhani SR, Reis-Filho JS, Fulford L, Penault-Llorca F, van der Vijver M, Parry S, et al. Prediction of BRCA1 status in patients with breast cancer using estrogen receptor and basal phenotype. Clin Cancer Res 2005;11:5175-80. (Pubitemid 41003703)
18. Sorlie T, Tibshirani R, Parker J, Hastie T, Marron JS, Nobel A, et al. Repeated observation of breast tumor subtypes in independent gene expression data sets. Proc Natl Acad Sci U S A 2003;100:8418-23. (Pubitemid 36842560)
19. Vargas AC, Silva LD, Lakhani SR. The contribution of breast cancer pathology to statistical models to predict mutation risk in BRCA carriers. Fam Cancer 2010;9:545-53.
20. Bane AL, Beck JC, Bleiweiss I, Buys SS, Catalano E, Daly MB, et al. BRCA2 mutation-associated breast cancers exhibit a distinguishing phenotype based on morphology and molecular profiles from tissue microarrays. Am J Surg Pathol 2007;31:121-8. (Pubitemid 46036911)
21. Weitzel JN, Robson M, Pasini B, Manoukian S, Stoppa-Lyonnet D, Lynch HT, et al. A comparison of bilateral breast cancers in BRCA carriers. Cancer Epidemiol Biomarkers Prev 2005;14:1534-8. (Pubitemid 40807358)
22. Lakhani SR, Manek S, Penault-Llorca F, Flanagan A, Arnout L, Merrett S, et al. Pathology of ovarian cancers in BRCA1 and BRCA2 carriers. Clin Cancer Res 2004;10:2473-81. (Pubitemid 38445709)
23. Rubin SC, Benjamin I, Behbakht K, Takahashi H, Morgan MA, LiVolsi VA, et al. Clinical and pathological features of ovarian cancer in women with germ-line mutations of BRCA1. N Engl J Med 1996;335:1413-6. (Pubitemid 26382501)
24. Shaw PA, McLaughlin JR, Zweemer RP, Narod SA, Risch H, Verheijen RH, et al. Histopathologic features of genetically determined ovarian cancer. Int J Gynecol Pathol 2002;21:407-11.
25. Chenevix-Trench G, Milne RL, Antoniou AC, Couch FJ, Easton DF, Goldgar DE. An international initiative to identify genetic modifiers of cancer risk in BRCA1 and BRCA2 mutation carriers: the Consortium of Investigators of Modifiers of BRCA1 and BRCA2 (CIMBA). Breast Cancer Res 2007;9:104.
26. Perrin-Vidoz L, Sinilnikova OM, Stoppa-Lyonnet D, Lenoir GM, Mazoyer S. The nonsense-mediated mRNA decay pathway triggers degradation of most BRCA1 mRNAs bearing premature termination codons. Hum Mol Genet 2002;11:2805-14. (Pubitemid 35331813)
27. Mazoyer S, Puget N, Perrin-Vidoz L, Lynch HT, Serova-Sinilnikova OM, Lenoir GM. A BRCA1 nonsense mutation causes exon skipping. Am J Hum Genet 1998;62:713-5. (Pubitemid 28164630)
28. Buisson M, Anczukow O, Zetoune AB, Ware MD, Mazoyer S. The 185delAG mutation (c.68-69delAG) in the BRCA1 gene triggers translation reinitiation at a downstream AUG codon. Hum Mutat 2006;27:1024-9. (Pubitemid 44454055)
29. Gayther SA, Mangion J, Russell P, Seal S, Barfoot R, Ponder BA, et al. Variation of risks of breast and ovarian cancer associated with different germline mutations of the BRCA2 gene. Nat Genet 1997;15:103-5. (Pubitemid 27014960)
30. Thompson D, Easton D. Variation in cancer risks, by mutation position, in BRCA2 mutation carriers. Am J Hum Genet 2001;68:410-9. (Pubitemid 32147810)
31. Surveillance, Epidemiology, and End Results (SEER) Program Limited-Use Data (1973-2006), National Cancer Institute, DCCPS, Surveillance Research Program, Cancer Statistics Branch, released April 2009, based on the November 2008 submission. www.seer.cancer.gov/.
32. Tung N, Miron A, Schnitt SJ, Gautam S, Fetten K, Kaplan J, et al. Prevalence and predictors of loss of wild type BRCA1 in estrogen receptor positive and negative BRCA1-associated breast cancers. Breast Cancer Res 2010;12:R95.
33. Lakhani SR, Khanna KK, Chenevix-Trench G. Are estrogen receptor-positive breast cancers in BRCA1 mutation carriers sporadic? Breast Cancer Res 2010;12:104.
34. Eerola H, Heikkila P, Tamminen A, Aittomaki K, Blomqvist C, Nevanlinna H. Relationship of patients' age to histopathological features of breast tumours in BRCA1 and BRCA2 and mutation-negative breast cancer families. Breast Cancer Res 2005;7:R465-9.
35. Anderson WF, Chatterjee N, Ershler WB, Brawley OW. Estrogen receptor breast cancer phenotypes in the Surveillance, Epidemiology, and End Results database. Breast Cancer Res Treat 2002;76:27-36. (Pubitemid 35178626)
36. Evans DG, Lalloo F, Cramer A, Jones EA, Knox F, Amir E, et al. Addition of pathology and biomarker information significantly improves the performance of the Manchester scoring system for BRCA1 and BRCA2 testing. J Med Genet 2009;46:811-7.
37. Mavaddat N, Rebbeck TR, Lakhani SR, Easton DF, Antoniou AC. Incorporating tumour pathology information into breast cancer risk prediction algorithms. Breast Cancer Res 2010;12:R28.
38. Tai YC, Chen S, Parmigiani G, Klein AP. Incorporating tumor immunohistochemical markers in BRCA1 and BRCA2 carrier prediction. Breast Cancer Res 2008;10:401.
39. Rakha EA, El-Sayed ME, Green AR, Paish EC, Powe DG, Gee J, et al. Biologic and clinical characteristics of breast cancer with single hormone receptor positive phenotype. J Clin Oncol 2007;25:4772-8. (Pubitemid 350086480)
40. Swain SM, Wilson JW, Mamounas EP, Bryant J, Wickerham DL, Fisher B, et al. Estrogen receptor status of primary breast cancer is predictive of estrogen receptor status of contralateral breast cancer. J Natl Cancer Inst 2004;96:516-23. (Pubitemid 38559575)
41. Sherman ME, Howatt W, Blows FM, Pharoah P, Hewitt SM, Garcia-Closas M. Molecular pathology in epidemiologic studies: a primer on key considerations. Cancer Epidemiol Biomarkers Prev 2010;19:966-72.
42. Melchor L, Honrado E, Huang J, Alvarez S, Naylor TL, Garcia MJ, et al. Estrogen receptor status could modulate the genomic pattern in familial and sporadic breast cancer. Clin Cancer Res 2007;13:7305-13.
43. Melchor L, Honrado E, Garcia MJ, Alvarez S, Palacios J, Osorio A, et al. Distinct genomic aberration patterns are found in familial breast cancer associated with different immunohistochemical subtypes. Oncogene 2008;27:3165-75. (Pubitemid 351693170)
44. Milne RL, Antoniou AC. Genetic modifiers of cancer risk for BRCA1 and BRCA2 mutation carriers. Ann Oncol 2011;22 Suppl 1:i11-17.
45. Garcia-Closas M, Hall P, Nevanlinna H, Pooley K, Morrison J, Richesson DA, et al. Heterogeneity of breast cancer associations with five susceptibility loci by clinical and pathological characteristics. PLoS Genet 2008;4:e1000054.
46. Broeks A, Schmidt MK, Sherman ME, Couch FJ, Hopper JL, Dite GS, et al. Low penetrance breast cancer susceptibility loci are associated with specific breast tumor subtypes: findings from the Breast Cancer Association Consortium. Hum Mol Genet 2011;20:3289-303.
47. Mulligan AM, Couch FJ, Barrowdale D, Domchek SM, Eccles D, Nevanlinna H, et al. Common breast cancer susceptibility alleles are associated with tumor subtypes in BRCA1 and BRCA2 mutation carriers: results from the Consortium of Investigators of Modifiers of BRCA1/2. Breast Cancer Res 2011;13:R110.